The c‐Src/LIST Positive Feedback Loop Sustains Tumor Progression and Chemoresistance

Xianteng Wang,Bing Wang,Fang Li,Xingkai Li,Ting Guo,Yushun Gao,Dawei Wang,Weiren Huang

DOI: https://doi.org/10.1002/advs.202300115

IF: 15.1

2023-05-10

Advanced Science

Abstract:This study provides novel insights into the exploration of efficient c‐Src agonists at the level of epigenetic regulation. lncRNA LIST and c‐Src are involved in a positive feedback regulatory loop during tumor resistance. Evolutionarily, this human‐specific c‐Src/LIST axis renders an additional yet critical layer of control over the c‐Src activity. Chemotherapy resistance and treatment failure hinder clinical cancer treatment. Src, the first mammalian proto‐oncogene to be discovered, is a valuable anti‐cancer therapeutic target. Although several c‐Src inhibitors have reached the clinical stage, drug resistance remains a challenge during treatment. Herein, a positive feedback loop between a previously uncharacterized long non‐coding RNA (lncRNA), which the authors renamed lncRNA‐inducing c‐Src tumor‐promoting function (LIST), and c‐Src is uncovered. LIST directly binds to and regulates the Y530 phosphorylation activity of c‐Src. As a c‐Src agonist, LIST promotes tumor chemoresistance and progression in vitro and in vivo in multiple cancer types. c‐Src can positively regulate LIST transcription by activating the NF‐κB signaling pathway and then recruiting the P65 transcription factor to the LIST promoter. Interestingly, the LIST/c‐Src interaction is associated with evolutionary new variations of c‐Src. It is proposed that the human‐specific LIST/c‐Src axis renders an extra layer of control over c‐Src activity. Additionally, the LIST/c‐Src axis is of high physiological relevance in cancer and may be a valuable prognostic biomarker and potential therapeutic target.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry